According to the study by Muller-Olling and colleagues [63], CP is the second most frequent investigational medicinal product evaluated in COVID-19-related clinical trials and increasing interest in this form of immunotherapy is documented by the fact that more than 140 clinical trials specifically evaluating CP in COVID-19 have been registered to date worldwide [63]. Here, CP is linked to COVID-19.